BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 35344520)

  • 1. Patterns of Adherence to a Dapivirine Vaginal Ring for HIV-1 Prevention Among South African Women in a Phase III Randomized Controlled Trial.
    Browne EN; Brown ER; Palanee-Phillips T; Reddy K; Naidoo L; Jeenarain N; Nair G; Husnik MJ; Singh D; Scheckter R; Soto-Torres L; Baeten JM; van der Straten A;
    J Acquir Immune Defic Syndr; 2022 Aug; 90(4):418-424. PubMed ID: 35344520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.
    Baeten JM; Palanee-Phillips T; Mgodi NM; Mayo AJ; Szydlo DW; Ramjee G; Gati Mirembe B; Mhlanga F; Hunidzarira P; Mansoor LE; Siva S; Govender V; Makanani B; Naidoo L; Singh N; Nair G; Chinula L; Parikh UM; Mellors JW; Balán IC; Ngure K; van der Straten A; Scheckter R; Garcia M; Peda M; Patterson K; Livant E; Bunge K; Singh D; Jacobson C; Jiao Y; Hendrix CW; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Torjesen K; Nel A; Rosenberg Z; Soto-Torres LE; Hillier SL; Brown ER;
    Lancet HIV; 2021 Feb; 8(2):e87-e95. PubMed ID: 33539762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
    Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
    J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Male Partner Involvement on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III HIV Prevention Trial.
    Roberts ST; Nair G; Baeten JM; Palanee-Philips T; Schwartz K; Reddy K; Kabwigu S; Matovu Kiweewa F; Govender V; Gaffoor Z; Singh N; Siva S; Naidoo K; Montgomery ET;
    AIDS Behav; 2020 May; 24(5):1432-1442. PubMed ID: 31667678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
    Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
    AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acceptability of the Dapivirine Vaginal Ring for HIV-1 Prevention and Association with Adherence in a Phase III Trial.
    Mayo AJ; Browne EN; Montgomery ET; Torjesen K; Palanee-Phillips T; Jeenarain N; Seyama L; Woeber K; Harkoo I; Reddy K; Tembo T; Mutero P; Tauya T; Chitukuta M; Gati Mirembe B; Soto-Torres L; Brown ER; Baeten JM; van der Straten A;
    AIDS Behav; 2021 Aug; 25(8):2430-2440. PubMed ID: 33713213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
    Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
    J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.
    Nel A; van Niekerk N; Van Baelen B; Malherbe M; Mans W; Carter A; Steytler J; van der Ryst E; Craig C; Louw C; Gwetu T; Mabude Z; Kotze P; Moraba R; Tempelman H; Gill K; Kusemererwa S; Bekker LG; Devlin B; Rosenberg Z;
    Lancet HIV; 2021 Feb; 8(2):e77-e86. PubMed ID: 33539761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
    Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
    J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study.
    Garcia M; Luecke E; Mayo AJ; Scheckter R; Ndase P; Kiweewa FM; Kemigisha D; Musara P; Mansoor LE; Singh N; Woeber K; Morar NS; Jeenarain N; Gaffoor Z; Gondwe DK; Makala Y; Fleurs L; Reddy K; Palanee-Phillips T; Baeten JM; van der Straten A; Soto-Torres L; Torjesen K
    BMC Public Health; 2021 Nov; 21(1):2041. PubMed ID: 34749675
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the Ring Work? Perceptions and Understanding of the Efficacy of a Dapivirine Vaginal Ring for HIV Prevention Amongst Women in a Placebo-Controlled Trial.
    Etima J; Katz AWK; Duby Z; Garcia M; Palanee-Phillips T; Reddy K; Mathebula F; Zimba C; Mansoor LE; Singh D; Manengamambo E; Naidoo S; Soto-Torres L; Montgomery ET;
    AIDS Behav; 2022 May; 26(5):1597-1606. PubMed ID: 34727272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
    Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
    J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acceptability of the dapivirine vaginal ring for HIV-1 prevention among women reporting engagement in transactional sex.
    Browne EN; Torjesen K; Mirembe BG; Palanee-Phillips T; Jeenarain N; Chitukuta M; Stoner MCD; Mansoor LE; Reddy K; Tauya TT; Naidoo L; Siva S; Richardson B; Dadabhai S; Seyama L; Soto-Torres L; van der Straten A;
    AIDS Care; 2024 Jan; 36(1):80-86. PubMed ID: 37066990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experiences with simultaneous use of contraception and the vaginal ring for HIV prevention in sub-Saharan Africa.
    Leslie J; Kiweewa F; Palanee-Phillips T; Bunge K; Mhlanga F; Kamira B; Baeten J; Katz A; Hillier S; Montgomery E;
    BMC Womens Health; 2021 Apr; 21(1):175. PubMed ID: 33892693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "It's already in your body and it's preventing": a qualitative study of African female adolescent's acceptability and preferences for proxy HIV prevention methods in Cape Town, South Africa.
    Fynn L; Gill K; Wallace M; Atujuna M; Duyver M; Ngcobo P; Spiegel H; Rinehart A; Hosek S; Bekker LG
    BMC Public Health; 2023 Nov; 23(1):2143. PubMed ID: 37919697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
    Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
    AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Self-reported removal and expulsion of the dapivirine vaginal ring: qualitative reports from female ring users and their male partners in the Ring Study (IPM 027).
    Milford C; Ramlal H; Mofokeng R; Rambally Greener L; Nel A; Smit J; Malherbe M
    BMC Public Health; 2024 May; 24(1):1458. PubMed ID: 38822304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
    Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
    Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Power of the Shared Experience: MTN-020/ASPIRE Trial Participants' Descriptions of Peer Influence on Acceptability of and Adherence to the Dapivirine Vaginal Ring for HIV Prevention.
    Katz AWK; Naidoo K; Reddy K; Chitukuta M; Nabukeera J; Siva S; Zimba C; Montgomery ET
    AIDS Behav; 2020 Aug; 24(8):2387-2399. PubMed ID: 31980993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.
    Nel A; van Niekerk N; Kapiga S; Bekker LG; Gama C; Gill K; Kamali A; Kotze P; Louw C; Mabude Z; Miti N; Kusemererwa S; Tempelman H; Carstens H; Devlin B; Isaacs M; Malherbe M; Mans W; Nuttall J; Russell M; Ntshele S; Smit M; Solai L; Spence P; Steytler J; Windle K; Borremans M; Resseler S; Van Roey J; Parys W; Vangeneugden T; Van Baelen B; Rosenberg Z;
    N Engl J Med; 2016 Dec; 375(22):2133-2143. PubMed ID: 27959766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.